Clinical Trials Logo

Amphetamine Addiction clinical trials

View clinical trials related to Amphetamine Addiction.

Filter by:

NCT ID: NCT05535101 Not yet recruiting - Depression, Anxiety Clinical Trials

Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The study aims to apply the intermittent theta burst transcranial magnetic stimulation (iTBS) treatment and evaluate the effect in improving craving, affective symptoms, and cognitive function for those participants in the community with amphetamine use. An electroencephalography and blood biomarkers will also be examined to explore the possible mechanisms.

NCT ID: NCT04993300 Completed - Depression, Anxiety Clinical Trials

Repetitive Transcranial Magnetic Stimulation in Amphetamine Addiction

Start date: February 17, 2022
Phase: N/A
Study type: Interventional

The study aims to test whether transcranial magnetic stimulation (TMS) improves the craving, depression, anxiety and cognitive function during the abstinent period of methamphetamine users.

NCT ID: NCT04687566 Recruiting - Clinical trials for Amphetamine Addiction

Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction

Start date: August 11, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators will conducted a randomized double-blind placebo-controlled study to investigate the treatment outcomes of add-on low dose dextromethorphan (DM), memantine (MM), or dextromethorphan and memantine combination (DM+MM) in amphetamine-type stimulants use disorder patients.

NCT ID: NCT04531384 Recruiting - Clinical trials for Amphetamine Addiction

Robot-Assisted Intelligent Rehabilitation Treatment for Methamphetamine Use Disorders.

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this research is to evaluate the efficacy and safety of Robot-assisted rehabilitation intelligent system as a virtual stand-alone treatment, delivered with minimal clinical monitoring compared with treatment as usual in methamphetamine (MA) use disorders.

NCT ID: NCT03318081 Completed - Clinical trials for Amphetamine Addiction

The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction

Start date: October 20, 2017
Phase: N/A
Study type: Interventional

The computerized cognitive rehabilitation therapy will be used to treat amphetamine-type stimulant (ATS) addiction.

NCT ID: NCT03221283 Completed - Clinical trials for Amphetamine Addiction

The Application of Music Therapy in Female Amphetamine Use Disorder

Start date: November 30, 2017
Phase: N/A
Study type: Interventional

The group music therapy will be used to treat female amphetamine-type stimulant (ATS) addiction

NCT ID: NCT02952196 Withdrawn - Clinical trials for Amphetamine Addiction

Cannabioids as a New Intervention for Amphetamine Dependence

Start date: November 2016
Phase: Phase 2
Study type: Interventional

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder. The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

NCT ID: NCT02950376 Completed - Clinical trials for Amphetamine Addiction

The Novel Addiction Assessment Study in Synthetic Drugs Addiction

Start date: December 2016
Phase:
Study type: Observational

The purpose of this research is to develop an objective assessment based on the virtual reality techniques which is used for evaluate addiction severity.

NCT ID: NCT02836756 Not yet recruiting - Clinical trials for Amphetamine Addiction

Cannabidiol as a New Intervention for Amphetamine Dependence

Start date: October 2016
Phase: Phase 2
Study type: Interventional

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). Cannabidiol (CBD), the second most abundant component of cannabis, is known for its broad spectrum of physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly CBD has been shown to be potentially helpful in treating addiction, due to its effects on various neuronal circuits involved in this disorder. Our overall hypothesis is that CBD is an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

NCT ID: NCT02713815 Completed - Clinical trials for Amphetamine Addiction

Novel Intervention for Amphetamine-type Stimulants Addiction

Start date: July 2016
Phase: N/A
Study type: Interventional

The repetitive transcranial magnetic stimulation (rTMS) will be used to treat amphetamine-type stimulant (ATS) addiction.